Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6 Pt 1
|
| pubmed:dateCreated |
1997-1-16
|
| pubmed:abstractText |
Inhalation of nitric oxide (NO) and prostacyclin (PGI2) may induce selective pulmonary vasodilation and-by improving ventilation-perfusion ratio in ventilated areas of the lung-increase Pao2 in patients with acute lung injury. To assess the therapeutic efficacy of both compounds, dose-response curves were established in patients with adult respiratory distress syndrome (ARDS). Patients received both PGI2 (doses of 1, 10, and 25 ng/kg/min) and NO (concentrations of 1, 4, and 8 ppm). Cardiorespiratory parameters were assessed at control, at each drug concentration, and after withdrawal of NO and PGI2. PGI2 resulted in a significant, dose-dependent and selective reduction of pulmonary artery pressure (PAP) from 35.1 +/- 6.3 mm Hg at control to 33.1 +/- 4.8 (1 ng/kg/min), 31.3 +/- 4.8 mm Hg (10 ng/kg/min) and 29.6 +/- 4.5 mm Hg (25 ng/kg/min), respectively. Inhaled NO reduced PAP from 34.5 +/- 5.6 to 32.1 +/- 5.9 mm Hg at 4 ppm, and to 31.8 +/- 6.1 mm Hg at 8 ppm, respectively, with no effect at 1 ppm. Pao2/Flo2 ratio increased from 105 +/- 37 to 125 +/- 56 mm Hg (range of increase: 0 to 57 mm Hg) at PGI2 10 ng/kg/min and to 131 +/- 63 mm Hg (range: -5 to 89 mm Hg) at 25 ng/kg/min with no effect at 1 ng/kg/min. NO improved Pao2 (e.g., from 116 +/- 47 to 167 +/- 86 mm Hg at 8 ppm) and reduced intrapulmonary shunt at all doses tested. We conclude that both inhaled PGI2 and NO may induce selective pulmonary vasodilation and increase Pao2 in severe ARDS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
154
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1671-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8970353-APACHE,
pubmed-meshheading:8970353-Administration, Inhalation,
pubmed-meshheading:8970353-Adult,
pubmed-meshheading:8970353-Dose-Response Relationship, Drug,
pubmed-meshheading:8970353-Epoprostenol,
pubmed-meshheading:8970353-Female,
pubmed-meshheading:8970353-Hemodynamics,
pubmed-meshheading:8970353-Humans,
pubmed-meshheading:8970353-Male,
pubmed-meshheading:8970353-Middle Aged,
pubmed-meshheading:8970353-Nitric Oxide,
pubmed-meshheading:8970353-Pulmonary Circulation,
pubmed-meshheading:8970353-Pulmonary Gas Exchange,
pubmed-meshheading:8970353-Respiratory Distress Syndrome, Adult,
pubmed-meshheading:8970353-Vasodilation,
pubmed-meshheading:8970353-Vasodilator Agents
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome.
|
| pubmed:affiliation |
Department of Anesthesiology, Ludwig-Maximilians-Universität München, Germany.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|